[Form 4] Stoke Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Jonathan Allan, General Counsel & Corporate Secretary of Stoke Therapeutics (STOK), reported multiple option exercises and open-market sales in late August and early September 2025. He exercised stock options at an exercise price of $7.07 on 08/29/2025 (850 shares) and 09/02/2025 (9,150 shares), and sold common stock in multiple transactions: 850 shares on 08/29/2025 at $20.00, 14,922 shares on 09/02/2025 at a weighted average $20.1375, and 6,345 shares on 09/03/2025 at a weighted average $20.0657. The filings state the sales were executed pursuant to a Rule 10b5-1 trading plan adopted 12/12/2024. After these transactions, the reporting person beneficially owned 11,831 shares of common stock and retained outstanding options covering additional shares.

Positive

• Sales executed under a Rule 10b5-1 trading plan, adopted 12/12/2024, indicating a pre-established, documented process for transactions
• Option exercises at $7.07 demonstrate conversion of in-the-money awards into shares rather than cashless exercises
• Filer retains equity: the Form 4 shows remaining beneficial ownership and outstanding option positions after transactions

Negative

• Significant share sales (totaling 21, unaggregated: 22,117 shares sold across dates) reduced the reporting person’s direct common stock position to 11,831 shares
• Large disposals at market prices (~$20.00–$20.40) materially monetized previously granted equity, which may reduce insider ownership concentration

Insights

Securities Analyst

TL;DR: Routine option exercises followed by scheduled sales under a 10b5-1 plan; neutral signaling absent other material facts.

The Form 4 shows exercise of options at $7.07 and subsequent open-market sales at roughly $20 per share under a pre-existing Rule 10b5-1 plan. These are standard executive liquidity events: the reporter converted in-the-money options and sold portions of the resulting shares in multiple tranches. The filing discloses weighted-average sale prices and confirms the 10b5-1 plan adoption date, improving compliance transparency. The reporter retains some equity through remaining common shares and unexercised/vested option positions disclosed in the derivative table.

Corporate Governance Expert

TL;DR: Transactions documented and executed under an established 10b5-1 plan, indicating procedural compliance.

The disclosure identifies the reporting person as General Counsel and Corporate Secretary and marks sales as pursuant to a Rule 10b5-1 plan adopted 12/12/2024. Using a trading plan reduces the risk of insider trading concerns if the plan was implemented while not in possession of material nonpublic information. The Form 4 includes full option vesting language and provides weighted-average sale prices with an undertaking to supply detailed per-trade breakdowns upon request, which supports regulatory transparency.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Allan Jonathan

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	GENERAL COUNSEL & CORP SEC

3. Date of Earliest Transaction (Month/Day/Year)
08/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/29/2025		M		850	A	$7.07	24,798	D
Common Stock	08/29/2025		S(1)		850	D	$20	23,948	D
Common Stock	09/02/2025		M		9,150	A	$7.07	33,098	D
Common Stock	09/02/2025		S(1)		14,922	D	$20.1375(2)	18,176	D
Common Stock	09/03/2025		S(1)		6,345	D	$20.0657(3)	11,831	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$7.07	08/29/2025		M			850	(4)	12/06/2032	Common Stock	850	$0	24,951	D
Stock Option (Right to Buy)	$7.07	09/02/2025		M			9,150	(4)	12/06/2032	Common Stock	9,150	$0	15,801	D

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.20, inclusive.

4. The option vested or vests as to 1/48th of the total award on January 7, 2023, with 1/48th of the total award vesting monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

	/s/ Jonathan Allan	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Jonathan Allan (STOK) report on Form 4?

He reported option exercises on 08/29/2025 (850 shares) and 09/02/2025 (9,150 shares) at a $7.07 exercise price, and open-market sales on 08/29/2025 (850 shares), 09/02/2025 (14,922 shares), and 09/03/2025 (6,345 shares).

Were the sales pursuant to a trading plan?

Yes. The Form 4 notes the sales were executed pursuant to a Rule 10b5-1 trading plan adopted December 12, 2024.

What prices were reported for the sales?

Reported weighted-average sale prices were approximately $20.00 (08/29/2025), $20.1375 (09/02/2025), and $20.0657 (09/03/2025); footnotes state per-trade ranges within those averages.

How many shares does the reporting person own after these transactions?

The Form 4 reports the reporting person beneficially owned 11,831 shares of common stock following the reported transactions.

Did the filer disclose option holdings after the transactions?

Yes. The derivative securities table shows option holdings and the number of underlying shares associated with the reported option awards after the transactions.